ArticleAlzheimer's research & therapy2022
Memory markers in the continuum of the Alzheimer's clinical syndrome.
Article in Alzheimer's research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The blood metabolome of brain health in midlife and influences of genes, microbiome and exposome.Nature aging · 2026Article
- Short-term memory conjunctive binding in subjective cognitive decline: A PET biomarker-based study.Journal of neurology · 2026Article
- Optimizing the Color Shapes Task for Ambulatory Assessment and Drift Diffusion Modeling: A Factorial Experiment.JMIR formative research · 2025Article
- Computational Phenotyping of Cognitive Decline With Retest Learning.The journals of gerontology. Series B, Psychological sciences and social sciences · 2025Article
- Oral Health Status and Factors Associated with Oral Health in Patients with Alzheimer's Disease: A Matched Case-Control Observational Study.Journal of clinical medicine · 2025Article
- Dementia and Mild Cognitive Impairment Identification in Illiterate and Low-Educated People: Systematic Review About the Use of Brief Cognitive Screening Tools.Behavioral sciences (Basel, Switzerland) · 2025Review
- Article
- Eye movements powered by artificial intelligence identify asymptomatic carriers of familial Alzheimer's disease.Brain communications · 2025Article
- Examining the Cognitive Underpinnings of Functional Decline in Prodromal Alzheimer's Disease: Insights From the Details of Functions of Everyday Life (DoFEL) Scale.Journal of aging research · 2025Article
- The blood metabolome of cognitive function and brain health in middle-aged adults - influences of genes, gut microbiome, and exposome.medRxiv : the preprint server for health sciences · 2024Article
- The memory binding test in a longitudinal study of cognitive aging and preclinical disease.Neuropsychology · 2024Article
- Exploring the Association between Amyloid-β and Memory Markers for Alzheimer's Disease in Cognitively Unimpaired Older Adults.The journal of prevention of Alzheimer's disease · 2024Article
- Consensus on rapid screening for prodromal Alzheimer's disease in China.General psychiatry · 2024Review
- The "when" matters: Evidence from memory markers in the clinical continuum of Alzheimer's disease.Neuropsychology · 2023Article
- Dual-stage cognitive assessment: a two-stage screening for cognitive impairment in primary care.BMC psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe individual and complementary value of the Visual Short-Term Memory Binding Test (VSTMBT) and the Free and Cued Selective Reminding Test (FCSRT) as markers to trace the AD continuum was investigated. It was hypothesised that the VSTMBT would be an early indicator while the FCSRT would inform on imminent progression.
methodsHealthy older adults (n=70) and patients with mild cognitive impairment (MCI) (n=80) were recruited and followed up between 2012 and 2017. Participants with at least two assessment points entered the study. Using baseline and follow-up assessments four groups were defined: Older adults who were healthy (HOA), with very mild cognitive but not functional impairment (eMCI), and with MCI who did and did not convert to dementia (MCI converters and non-converters).
resultsOnly the VSTMBT predicted group membership in the very early stages (HOA vs eMCI). As the disease progressed, the FCSRT became a strong predictor excluding the VSTMB from the models. Their complementary value was high during the mid-prodromal stages and decreased in stages closer to dementia. DISCUSSION: The study supports the notion that neuropsychological assessment for AD needs to abandon the notion of one-size-fits-all. A memory toolkit for AD needs to consider tools that are early indicators and tools that suggest imminent progression. The VSTMBT and the FSCRT are such tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.